Antibiotics use strongly linked with SJ Syndrome and Toxic Epidermal Necrolysis, sulfonamides worst offenders

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-02-17 04:45 GMT   |   Update On 2023-02-17 07:15 GMT
Advertisement

Antibiotics use strongly linked with SJ Syndrome and Toxic Epidermal Necrolysis, sulfonamides worst offenders suggests a new study published in the JAMA Dermatology

Antibiotics are an important risk for Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), which are the most severe types of drug hypersensitivity reaction with a mortality rate up to 50%. To our knowledge, no global systematic review has described antibiotic-associated SJS/TEN.

Advertisement

A study was conducted to evaluate the prevalence of antibiotics associated with SJS/TEN worldwide.

The MEDLINE and Embase databases were searched for experimental and observational studies that described SJS/TEN risks since database inception to February 22, 2022.

Study Included studies adequately described SJS/TEN origins and specified the antibiotics associated with SJS/TEN. Two reviewers (E.Y.L. and C.K.) independently selected the studies, extracted the data, and assessed the risk of bias. A meta-analysis using a random-effects model was performed in the studies that described patient-level associations. Subgroup analyses were performed to explore the heterogeneity. The risk of bias was assessed using the Joanna Briggs Institute checklist, and the certainty of evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Prevalence of antibiotic-associated SJS/TEN was presented as pooled proportions with 95% CIs.

Results

• Among the 64 studies included in the systematic review, there were 38 studies that described patient-level associations; the meta-analysis included these 38 studies with 2917 patients to determine the prevalence of single antibiotics associated with SJS/TEN.

• The pooled proportion of antibiotics associated with SJS/TEN was 28% , with moderate certainty of evidence.

• Among antibiotic-associated SJS/TEN, the sulfonamide class was associated with 32% of cases, followed by penicillins , cephalosporins, fluoroquinolones, and macrolides

• There was a statistically significant heterogeneity in the meta-analysis, which could be partially explained in the subgroup analysis by continents.

• The overall risk of bias was low using the Joanna Briggs Institute checklist for case series.

In this systematic review and meta-analysis of all case series, antibiotics were associated with more than one-quarter of SJS/TEN cases described worldwide, and sulfonamide antibiotics remained the most important association. These findings highlight the importance of antibiotic stewardship, clinician education and awareness, and weighing the risk-benefit assessment of antibiotic choice and duration.

Reference:

Lee EY, Knox C, Phillips EJ. Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. Published online February 15, 2023. doi:10.1001/jamadermatol.2022.6378

Keywords:

JAMA Dermatology, Antibiotics use, strongly, linked, SJ Syndrome, Toxic Epidermal Necrolysis, sulfonamide, offenders, Lee EY, Knox C, Phillips EJ

Tags:    
Article Source : JAMA Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News